tumor regressions in an EGFR L858R PDX tumor model generated from a residual disease surgical specimen. Conclusion: This synthetic lethal interaction between EGFR TKIs and Aurora kinase inhibitors has important clinical implications for the development of better treatment strategies using EGFR-TKIs and suggest a new paradigm for preventing the emergence of resistance.
Background: Greater than 40% of lung adenocarcinomas (LUAD) contain no known driver mutations from point mutation or structural variance analysis. Recently, we discovered that 15-20% of LUAD have abnormally high levels of ASCL1, a key regulator of neuroendocrine differentiation in the lung. ASCL1 in these tumors orchestrates the expression of a network of genes that affect the behavior of tumors and their microenvironments and provide opportunities for treatment that has largely been understudied. The goal of this study was to explore potential therapeutic options in these tumors. Method: Bioinformatics analyses used public and internally generated expression data from LUAD. In vitro co-immunoprecipitation and cytotoxicity assays were used to determine the interaction between proteins and the sensitivity to EGFR blockers gefitinib and lapatinib. These drugs were also tested in patient derived xenograft (PDX) models from cisplatin resistant brain met LUAD with (A + AD) and without (A -AD) ASCL1 expression. Result: Our data demonstrated that ASCL1 acts upstream of RET and promotes chronic over-expression of the oncogene in A + AD. In vitro experiments revealed a strong interactions between wild type EGFR and RET in A + AD which rendered these tumors vulnerable to treatment by EGFR blockers. Furthermore, while EGFR inhibitors blocked tumor growth in the A + AD PDX model, they were completely ineffective in the A -AD PDX model. EGFR therapy also markedly changed key regulators of the tumor microenvironment in favor of anti-tumor immunity. Analysis of TCGA data identified some overlap between A + AD and other LUAD subtypes, such as KRAS or EGFR mutant tumors. Further meta-analysis in a compendium of microarray data in stage-1 LUAD from multiple institutions demonstrated that high expression of wild type RET was significantly associated with a poor overall survival. Furthermore, high expression of EGFR (or its ligand TGFA) and RET imparted an aggressive phenotype in A + AD with overall survival similar to small cell lung cancer. Notably, EGFR, TGFA, and RET did not have any prognostic value in A -AD. Conclusion: Our data provide strong evidence that patients with A + AD may benefit from a multipronged treatment strategy that include EGFR therapy even in the absence of mutations in EGFR. Background: Non-small cell lung cancer (NCSLC) harboring epidermal growth factor receptor (EGFR) mutation shows favorable response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, almost all these patients eventually acquire resistance to EGFR-TKIs, and novel therapeutic strategies to overcome the acquired resistance have been required. The 90-kDa heat shock protein (HSP90) is a
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